The Pharma Data

JANUARY 19, 2021

The company hopes to raise $140 million of common stock, which will be used to advance its clinical and earlier stage programs and for R&D, working capital and general corporate purposes. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is based in Suzhou and Shanghai, China.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

PPD

NOVEMBER 30, 2023

Nearly half of the group predicted that 90% of their trials will include decentralized elements by 2025. This fundamental step will create more efficacious therapies by developing and researching their effects in a more inclusive population.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

PPD

MAY 7, 2024

The European Union (EU) is on the verge of a significant shift as it prepares to implement new health technology assessment (HTA) regulations in 2025. This harmonization aims to enhance the efficient use of resources, reduce duplication in HTA submissions and address inequities in patient access to innovative therapies.

Regulations 52

Regulations Pharmaceutical Companies International Pharmaceuticals 52

The Pharma Data

NOVEMBER 26, 2020

The EGM resolved to approve the Board of Directors’ previous resolution on October 27, 2020 on a directed issue of 29,395,311 new shares and 14,697,655 new warrants of series 2020/2025, both to CASI Pharmaceuticals, Inc. per share during the period from and including 27 November 2020 up to and including 27 November 2025.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52

Disease Science Therapies Production 52

The Pharma Data

AUGUST 3, 2021

The R&D pipeline in Human Pharma comprises more than 60 new substances and around 100 clinical and pre-clinical projects. This pipeline has the potential to deliver up to 15 medicines for approval by 2025. More than 60 million patients worldwide suffer from this disease, approx.

Research 52

Research Treatment Clinical Trials Production 52

The Pharma Data

JANUARY 10, 2021

In 2019, we introduced Vision 3×3, the company’s strategic roadmap through 2025, to build a leading biopharma company by achieving sustainable growth through multiple approaches. We expect 2021 will mark a number of key clinical and commercial milestones. COPENHAGEN, Denmark, Jan. Morgan Healthcare Conference. “In ?. .

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

LifeSciVC

AUGUST 21, 2024

At this point of the year, the JPMorgan conference seems like ancient history and you are looking into flights for JPM 2025. I am fortunate to have a great Tech Ops team at Lifordi who is on top of managing all the moving parts across the globe for making tox and clinical supply for us. These goals were believable and achievable.

Clinical Trials 72

Clinical Trials Trials Disease Treatment 72

The Pharma Data

JANUARY 15, 2021

Enhertu previously received Priority Review and Breakthrough Therapy Designation (BTD) in the U.S. About the Enhertu Clinical Development Program. for the treatment of patients with metastatic non-small cell lung cancer whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.

Treatment 52

Treatment Trials Disease Therapies 52

The Pharma Data

NOVEMBER 10, 2020

Billion by 2025. Phase1b/2 clinical study to be conducted in the United States and several European countries. This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. billion by 2025, according to Grand View Research 1.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

DECEMBER 12, 2020

Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca’s broad-based revenue and the company will further globalise Alexion’s portfolio . In contrast, AstraZeneca’s capabilities in genomics, precision medicine and oligonucleotides can be leveraged to develop medicines targeting less-frequent diseases.

Regulations 75

Regulations International Disease Small Molecule 75

Agency IQ

DECEMBER 1, 2023

If all changes are accepted, the date of application is set to be January 1, 2025. Regulation Link Description of the Guideline Action Planned Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus Addresses the E.U.’s

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

LifeSciVC

JANUARY 21, 2025

While many early-stage private VCs (and especially those participating in recent M&A) are feeling good going into 2025, public investors lamented the poor performance of public portfolios and indices. Herculean Clinical Impact: What Cant Incretins Do?! overall sentiment was bifurcated.

Trials 123

Trials Small Molecule Marketing Disease 123

PPD

MARCH 19, 2025

Drug developers should consider several approaches when implementing an FSP partnership that is fit-for-purpose and positioned for optimal performance. Better manage complexity with the right expertise One of the most critical success factors in the clinical development landscape is having the right team.

Clinical Development 52

Clinical Development Drug Development Clinical Research Drugs 52

Drug Target Review

APRIL 1, 2025

Advances in biotechnology are driving significant progress in the treatment of rare diseases, making it possible to develop targeted therapies for previously untreatable conditions. Founded in 2021, SynaptixBio is working to develop therapies for TUBB4A leukodystrophies – a group of rare and severe neurological disorders.

Disease 52

Disease Therapies Clinical Trials Cell Biology 52

PPD

JANUARY 21, 2025

As 2025 kicks off, the biopharma and biotech industries find themselves at a pivotal juncture, navigating an era of rapid transformation marked by new technological advancements, evolving regulations and shifting industry priorities. However, amid this progress, the complexities of drug development have never been more apparent.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

New Drug Approvals

APRIL 8, 2025

Vimseltinib 1628606-05-2 DCC-3014 2/14/2025 FDA APPROVED, Romvimza 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one C 23 H 25 N 7 O 2 , 431.5 2] Vimseltinib was approved for medical use in the United States in February 2025. [2] 18 February 2025. 14 February 2025.

FDA Approval 62

FDA Approval FDA Clinical Development Treatment 62

Drug Target Review

MARCH 10, 2025

Antibody-drug conjugates (ADCs) hold immense promise for targeted cancer therapy, but challenges remain in maximising their efficacy and minimising toxicity. ADC Therapeutics (ADCT) is tackling these challenges head-on with its next-generation ADC development programme, focused on a novel exatecan-based platform.

Therapies 52

Therapies Drugs Research Clinical Development 52